Document:

<PAGE>

                                                                   Exhibit 10.11

                                LICENSE AGREEMENT

     THIS AGREEMENT, effective this 2nd day of March 1994, ("EFFECTIVE DATE") by
and between BROWN UNIVERSITY, an educational institution located in Providence,
Rhode Island and its technology licensing agent BROWN UNIVERSITY RESEARCH
FOUNDATION, a corporation duly organized and existing under the laws of the
State of Rhode Island and having a principal office at 42 Charlesfield Street,
Providence, Rhode Island 02912 (hereinafter collectively referred to as
"BROWN"), and SPECTRA SCIENCE CORPORATION, a corporation duly organized and
existing under the laws of the State of Delaware ("LICENSEE") and having a
principal office at 300 Metro Center, Warwick, Rhode Island 02886.

     WHEREAS, BROWN is the owner of certain inventions related to laser emission
in high gain, strongly scattering media; and

     WHEREAS, BROWN desires to have such inventions and any resulting patent
rights used in the public interest and is willing to grant a license thereto on
the terms set forth below; and

     WHEREAS, LICENSEE desires to obtain a license for such inventions and any
resulting patent rights upon the terms and conditions hereinafter set forth;

     NOW, THEREFORE, in consideration of the premises and covenants contained
herein, the parties hereto agree as follows:

                             ARTICLE 1 - DEFINITIONS

     For the purpose of this Agreement, the following words and phrases shall
have the following meanings:

     1.1 "FIRST COMMERCIAL SALE" shall mean the initial transfer by LICENSEE or
its sublicensee, to an unrelated third party of LICENSED PRODUCTS subject to
royalties hereunder for commercial use and not for research, development or
testing purposes.

     1.2 "LICENSED PRODUCTS" shall mean any product the manufacture, use or sale
of which is within the claims of the PATENT RIGHTS.

     1.3 "NET SALES" shall mean the gross sales collected from unrelated third
party customers by LICENSEE for LICENSED PRODUCTS, less the sum of (a)
transportation, insurance, handling charges, discounts, and returns, (b)
commissions and other fees in amounts customary in the trade paid to third party
distributors and other sales agencies and (c) sales, excise, turnover and
similar taxes and any duties and other governmental charges imposed upon the
production, importation, use or sale of such LICENSED PRODUCTS.

<PAGE>

     In the event that (i) LICENSEE shall manufacture and/or sell an instrument
or system (a "System"), which consists of more than one component or device, and
(ii) one or more of the components or devices in the System is within the claims
of the PATENT RIGHTS ("Patented Components"), and one or more of the components
or devices in the System is not within the claims of the PATENT RIGHTS
("Unpatented Components"), then for the purposes of this Agreement, the Patented
Components shall be deemed to be LICENSED PRODUCTS and subject to payment of
royalties hereunder, but the Unpatented Components and the entire System shall
not be LICENSED PRODUCTS and shall not be subject to the payment of royalties
hereunder. The NET SALES with respect to any such Patented Component shall be
calculated as a proportion of the NET SALES of the System, based on the separate
selling prices of the individual Patented Components and Unpatented Components
included therein, or, if all of such Patented Components and Unpatented
Components are not sold separately, then based on the relative value of the
Patented Components and the Unpatented Components and the technology embodied
therein, which relative value shall be negotiated in good faith by the parties.
In the event the parties are not able to agree on such relative value, it will
be determined by submission to arbitration in accordance with Section 12.5
hereof. In construing this Section, it is the intention of the parties that a
royalty be paid only on that portion of a System which, if sold separately,
would infringe any of the PATENT RIGHTS. An instrument or Component will be
deemed a separate instrument or component if such instrument or component is
capable of functioning either independently, or in combination with additional
separate instruments or components of the type generally available in the
market. For example, if Spectra sells a product consisting of a laser, a
separate power supply, and a computer which operates and controls the laser, and
if the laser contains a laser tube which is within the claims of the PATENT
RIGHTS, as well as other optical, electronic and mechanical components, then,
not withstanding such other electrical and mechanical components the entire
laser would be a Patented Component and subject to royalty hereunder, but the
entire System and the computer and power supply would not be subject to royalty
hereunder.

     1.4 "PATENT RIGHTS" shall mean (a) any United States or foreign patent
applications owned or controlled by BROWN based upon or claiming the TECHNOLOGY;
(b) any divisions, continuations, continuations-in-part, re-examinations,
additions, reissues or extensions based thereon; and (c) any United States or
foreign patent or other industrial property rights obtained from, derived from
or claiming priority or benefit from, any of such United States or foreign
patent applications.

     1.5 "RESEARCH AGREEMENT" shall mean the research support agreement between
Brown University and LICENSEE dated February 25, 1994.

     1.6 "TECHNOLOGY" shall mean [***].

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

                                      -2-

<PAGE>

                         ARTICLE 2 - OWNERSHIP AND GRANT

     2.1 Ownership. LICENSEE agrees to assign to BROWN any interest that
LICENSEE may possess by virtue of co-inventorship by LICENSEE'S employees of the
PATENT RIGHTS and/or any improvements or new inventions arising out of the
RESEARCH AGREEMENT.

     2.2 Grant. Brown hereby grants to Licensee, subject to the terms herein
recited, an exclusive, non-transferable (except as provided in ARTICLE 9
herein), perpetual, royalty-bearing, worldwide right and license, with the right
to grant sublicenses, under the PATENT RIGHTS to develop, make, have made, use,
sell and distribute (directly or indirectly through third parties) LICENSED
PRODUCTS.

     2.3 Reservation of Research Rights. Anything to the contrary
notwithstanding, BROWN reserves the right to use the PATENT RIGHTS and
TECHNOLOGY for its own academic, non-commercial scientific research purposes.

     2.4 Non-Assertion of Patent Rights. During the term of this Agreement and
so long as LICENSEE is not in default with respect to any payment due to BROWN
hereunder, BROWN will not assert its rights under the PATENT RIGHTS to prevent
any party from using or selling any quantity of product on which royalty has
been paid hereunder.

                              ARTICLE 3 - ROYALTIES

     3.1 License Fee. Upon signing this Agreement, LICENSEE shall pay BROWN a
license fee of [***].

     3.2 Royalties. Beginning with the first COMMERCIAL SALE and subject to the
terms hereof, LICENSEE agrees to pay to BROWN, as partial consideration for the
rights granted under this Agreement, an amount equal to [***] of NET SALES of
LICENSED PRODUCTS within the claims of an issued patent which is part of the
PATENT RIGHTS.

     3.3 Sublicenses. In the event that LICENSEE enters into a sublicense,
LICENSEE shall pay to BROWN [***] of any royalty payments received by LICENSEE
under such sublicense with respect to the sale by the sublicensee of LICENSED
PRODUCTS within the claims of an issued patent which is part of the PATENT
RIGHTS. In no event will equity investments in LICENSEE or payments for research
and development conducted by LICENSEE be considered to be royalty payments.
LICENSEE shall not offer sublicense royalty rates less than the rate that would
be due under Section 3.2 for NET SALES of LICENSEE without the written prior
approval of BROWN.

     3.4 Royalty Period. The obligation to pay royalties under Section 3.2 and
3.3 shall continue in each country in which sales are made until the date of
expiration of the last to expire of any patent issued in such country which is
part of the PATENT RIGHTS, whereupon the exclusive licenses granted hereunder
shall be fully paid and LICENSEE and its affiliates and sublicensees shall be
free to develop, make, have made, use, sell and distribute LICENSED PRODUCTS in
such country without further duties or responsibilities to BROWN.

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

                                      -3-

<PAGE>

     3.5 License Maintenance Fee. In order to keep this Agreement in force,
LICENSEE shall pay BROWN an annual maintenance fee of [***] and [***] no later
than [***], and [***] no later than [***] each successive year during the term
of this Agreement. Such license maintenance fees shall be creditable against
royalties due hereunder.

     3.6 Payment. Royalties will be due and payable within forty-five (45) days
of the end of each calendar quarter. Royalty payments shall be made in United
States Dollars in Providence, Rhode Island. Exchange rates applied will be the
closing buying rates quoted by the Wall St. Journal on the last business day of
the applicable calendar quarter.

     3.7 Joint Intellectual Property. The royalty rates defined above in
paragraphs 3.2 and 3.3 shall apply to all Patent Rights derived from the
technology (i.e. based upon an initial draft patent application presently being
prepared to claim the subject matter of the Lawandy et al. draft publication) as
well as any continuations, additions, divisions, continuations-in-part,
reissuances, or other continuing applications which claim the priority of such
initial application and whether or not the initial application or any of the
continuing applications names one or more employees of LICENSEE as co-inventors
together with BROWN employees. If, however, a distinct improvement or invention
is made subsequent to the execution of this AGREEMENT and is the subject of a
separate patent application which names both LICENSEE'S employees and BROWN
employees as co-inventors, then the applicable royalty rate shall be one-half
the royalty rate set forth in Section 3.2 or 3.3.

     3.8 [***]

     3.9 Only One Royalty Payable. Only one royalty will be paid with respect to
any particular product, regardless of the number of inventions within the claims
of PATENT RIGHTS which are included therein. If different royalty rates apply to
different inventions, the highest royalty rate will apply to the product.

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

                                      -4-

<PAGE>

                         ARTICLE 4 - REPORTS AND RECORDS

     4.1 Reports. LICENSEE shall report to BROWN quarterly on its efforts to
bring the TECHNOLOGY into broad commercial use and shall provide copies of all
sublicenses granted. At the time of each royalty payment, LICENSEE shall provide
a full account of all business activities subject to royalty payments hereunder.
The quarterly report by LICENSEE shall also attest to compliance by LICENSEE
with the insurance provisions of Article 8, below, if applicable as result of
clinical trials or commercial activities, and shall further include a copy of
the insurance policy currently in force.

     4.2 Records. LICENSEE shall keep, and shall require its sublicensees to
keep, complete and accurate books of account containing all particulars which
may be reasonably necessary for the purpose of showing the royalties payable to
BROWN. Said books of account of LICENSEE shall be kept at LICENSEE's principal
place of business or the principal place of business of a division of LICENSEE
which is marketing LICENSED PRODUCTS. Said books and particulars shall be
available during normal business hours, upon reasonable notice, for two (2)
years following the end of the calendar year to which they pertain, to the
inspection, not more than once during any calendar year, of an independent
certified public accountant retained by BROWN, and reasonably acceptable to
LICENSEE, for the purpose of verifying LICENSEE records directly related to
LICENSEE royalty obligations under this Agreement. Said certified public
accountant shall be required to enter into reasonable confidentiality agreements
provided by LICENSEE prior to any inspection.

     4.3 Audit Costs. If an audit conducted on behalf of BROWN pursuant to
Section 4.1 reveals that LICENSEE has made an error of five percent (5%) or more
in its favor of the sum of royalty payments due BROWN in a calendar year,
LICENSEE shall be obliged to pay the audit fee in connection with the audit.
Except for the provision in the prior sentence, BROWN shall be responsible for
all fees and expenses of said independent certificate public accountant.

     4.4 Marking. LICENSEE agrees to mark and to require and its sublicensees to
mark all LICENSED PRODUCTS or associated packaging sold in the United States
with all applicable U.S. patent numbers, to the extent commercially practicable.
ALL LICENSED PRODUCTS shipped to or sold in other countries shall be marked in
such a manner as to conform with the patent laws and practice of the country to
which such products are shipped or in which such products are sold, to the
extent commercially practicable.

                 ARTICLE 5 - PATENT PROSECUTION AND ENFORCEMENT

     5.1 Initiation of patent application. As soon as practicable following the
signing of this Agreement, LICENSEE shall engage patent counsel reasonably
acceptable to BROWN to prepare and file a U.S. Patent Application in the name of
Brown University Research Foundation covering the patentable aspects of the
TECHNOLOGY.

                                      -5-

<PAGE>

     5.2 Applications. For so long as this Agreement shall be in effect, BROWN
hereby authorizes LICENSEE, in the name of Brown University Research Foundation
and as its agent, at LICENSEE's expense, to apply for and seek prompt issuance
of, and, upon issuance, maintain during the term of this Agreement patents
worldwide as described in the PATENT RIGHTS or as may otherwise arise as a
result of new inventions or improvements made in the course of the RESEARCH
AGREEMENT. LICENSEE shall apply all reasonable efforts to obtain broad patent
claims. BROWN hereby agrees to take all actions necessary to cooperate with and
assist LICENSEE in the filing and prosecution of such patent applications.
LICENSEE shall keep BROWN informed as to the status of such patent applications
including providing BROWN with copies of all written communications with the
patent offices, and consulting with BROWN on responses to patent offices in
advance of submission. The filing, continued prosecution and maintenance of
patent applications, patents, and patent rights shall, after consultation with
BROWN, be within the discretion of LICENSEE provided, however, if LICENSEE in
its discretion elects not to file, or decides to discontinue prosecution of,
such patent applications or maintain such patents of TECHNOLOGY which is owned
or controlled by BROWN, BROWN may do so as its own expense and such patents,
patent applications, and resulting patents shall henceforth be excluded from the
PATENT RIGHTS licensed hereunder. If LICENSEE decides not to maintain patent
applications, patents, or patent rights already in existence, LICENSEE will give
BROWN at least ninety (90) days prior written notice before any expiration date
for response or action required by the U.S. Patent Office or any foreign patent
office. LICENSEE will provide BROWN with reasonable cooperation in the transfer
of responsibility for the maintenance of such patent applications, patents, or
patent rights.

     5.3 Enforcement. BROWN and LICENSEE shall each give immediate notice to the
other of any infringement of PATENT RIGHTS by third parties which may come to
their attention. BROWN hereby grants LICENSEE, at LICENSEE's expense, the right
to institute and conduct such legal action against third party infringers of the
PATENT RIGHTS and/or unauthorized users of TECHNOLOGY, or enter into such
settlement agreements, as are deemed appropriate by LICENSEE. The benefits of
any action taken by LICENSEE shall first be applied to reimbursing LICENSEE's
reasonable expense for such action and then shall be treated as sublicense
royalty payments hereunder, upon which LICENSEE shall be obligated to pay a
royalty. In any such action, LICENSEE shall be entitled to join BROWN as a party
plaintiff and BROWN will be obligated to reasonably assist at LICENSEE's
expense. Should LICENSEE fail to commence actions or proceedings against
infringers of the PATENTS or unauthorized users of the TECHNOLOGY within sixty
(60) days of receiving written notice thereof from BROWN, BROWN, at BROWN's
expense, shall have the right to initiate and pursue such action and receive all
resulting benefits. If BROWN fails to take such an action within sixty (60) days
of receiving written notice from LICENSEE, LICENSEE shall again have such right
and authority to take such actions as set forth in this Section 5.3.

                                      -6-

<PAGE>

                   ARTICLE 6 - REPRESENTATIONS AND WARRANTIES

     6.1 Ownership. BROWN warrants to its best knowledge and belief that it is
the owner of the PATENT RIGHTS and TECHNOLOGY and that any resultant patents are
free of any liens, encumbrances, restrictions and other legal or equitable
claims from third parties. BROWN warrants that it is not aware of any claims
that the PATENT RIGHTS or TECHNOLOGY infringe the intellectual property rights,
including patents, of third parties. BROWN warrants that it is not aware and
believes that no third party has asserted the existence of any right, title or
interest in or to the PATENT RIGHTS or TECHNOLOGY and no third party has alleged
that the PATENT RIGHTS OR TECHNOLOGY infringe the intellectual property rights,
including patents, of a third party.

     6.2 Utilization. LICENSEE represents and warrants that it intends to use
commercially reasonable efforts to exploit the PATENT RIGHTS and the TECHNOLOGY
so that utilization will result therefrom.

     6.3 Authority. Each party represents and warrants that it has the right and
authority to enter this Agreement.

     6.4 Exceptions. Nothing in this Agreement shall be construed as:

          (A) a warranty or representation that anything made, used, sold or
otherwise disposed of under any license granted in this Agreement is or will be
free from infringement of patents, copyrights and trademarks of third parties;

          (B) conferring rights on BROWN to use in advertising, publicity or
otherwise the name of LICENSEE or of its employees, affiliates or sublicensees
without the prior written approval of LICENSEE; and

          (C) conferring rights on LICENSEE to use in advertising, publicity or
otherwise the name of "Brown University" or its employees without prior written
approval of BROWN.

     6.5 Disclaimer. EXCEPT AS EXPRESSLY PROVIDED HEREIN, BROWN MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE THE PARTIES ACKNOWLEDGE THAT THIS AGREEMENT IS
NOT A CONSUMER TRANSACTION UNDER THE UNIFORM COMMERCIAL CODE OF RHODE ISLAND.
BROWN has not conducted any study of the patentability of the TECHNOLOGY and
makes no representations or Warrantee of any kind with regard to the
patentability of any aspect of the TECHNOLOGY.

                                      -7-

<PAGE>

                        ARTICLE 7 - TERM AND TERMINATION

     7.1 Bankruptcy. If LICENSEE undergoes a liquidation in bankruptcy, or files
a petition for liquidation in bankruptcy, or applies for or consents to the
appointment of a receiver or trustee, or makes an assignment for the benefit of
creditors, whether by the voluntary act of LICENSEE or otherwise, and if
LICENSEE fails to terminate any such proceeding within one hundred twenty (120)
days after its commencement, BROWN may at its election terminate this Agreement
upon thirty (30) days written notice to LICENSEE. LICENSEE agrees to provide
written notice to BROWN of LICENSEE's or third party's intention to file a
petition for liquidation of LICENSEE in bankruptcy prior to such filing, if
known.

     7.2 Failure to Pay Royalties. Should LICENSEE fail in its payment to BROWN
of royalties due in accordance with the terms of this Agreement, BROWN shall
have the right, subject to LICENSEE's right hereunder to dispute any amounts
due, to serve notice upon LICENSEE by certified mail at an address designated in
Article 11 hereof, of its intention to terminate this Agreement within ninety
(90) days after receipt of said notice of termination unless LICENSEE shall pay
BROWN within the ninety (90) day period, and if the amount of royalties due is
uncontested by LICENSEE, the rights, privileges and license granted hereunder
shall terminate upon the end of such ninety (90) day period if such amount
remains unpaid. Upon the receipt by BROWN of a royalty payment from LICENSEE,
BROWN shall have a period of sixty (60) days to send a notice to LICENSEE of its
intention to dispute the amount due regarding such payment. Upon receipt by
LICENSEE of a notice pursuant to the first sentence of this Section, LICENSEE
shall, during the ninety (90) day period referred to therein have a right to
send a notice to BROWN of its dispute of BROWN's claim. In either case, upon
receipt of such notice, the parties hereto will work expeditiously and in good
faith in an attempt to resolve such disputes within a period of ninety (90) days
after the date of such notice, failing which such disputes shall be submitted
for determination to a national accounting firm mutually decided upon by both
parties; the determination of the accounting firm shall be made within
forty-five (45) days, shall be final and binding on the parties hereto and not
subject to appeal (the "FINAL DECISION"), and any payment by a party to the
other party following the resolution of any dispute in accordance with the
foregoing shall be made forthwith upon such a resolution. The cost and expenses
of the accounting firm shall be borne equally by the parties hereto. LICENSEE
and BROWN shall each bear their own costs in presenting their respective cases
to the accounting firm. In the even that royalties are due after the resolution
of such dispute, the amount due shall accrue simple interest at the average
prime rate plus two (2) as established in the Wall Street Journal for the period
from the date such amount shall have been due until such amount is paid in full.

                                      -8-

<PAGE>

     7.3 Material Breach. Upon any material breach or default by LICENSEE or the
failure of LICENSEE to pay the amounts set forth in Exhibit B to the Research
Agreement, unless the Research Agreement has been terminated, BROWN shall have
the right to terminate this Agreement and the rights and license granted
hereunder by ninety (90) days notice by certified mail to LICENSEE. Such
terminations hall become effective at the end of such ninety (90) day period
unless LICENSEE has cured or has commenced reasonable good faith efforts to cure
any breach or default prior to the expiration of the ninety (90) day period.
Notwithstanding the foregoing, BROWN may not terminate this Agreement based on
non-payment of royalties unless and until there has been a FINAL DECISION
pursuant to Section 7.2 and LICENSEE has failed to pay the amount required by
the FINAL DECISION within thirty (30) days of the date thereof.

     7.4 Termination by LICENSEE. LICENSEE may terminate this Agreement upon
ninety (90) days notice by certified mail to BROWN.

     7.5 Obligations on Termination. Upon termination of this Agreement for any
reason, nothing herein shall be construed to release either party from any
obligation which matured prior to the effective date of such termination, and
LICENSEE, LICENSEE's affiliates, and LICENSEE's sublicensees may, after the
effective date of such termination, complete LICENSED PRODUCTS in the process of
manufacture at the time of such termination and sell the same together with
LICENSED PRODUCTS in inventory at the effective date of such termination,
provided that LICENSEE pays to BROWN royalties as required by Article 3 of this
Agreement and submits the reports required by Article 4.

     7.6 Survival. Sections 4.2, 5.3, 6.1, 6.4, 14.2 and 14.3 shall survive
termination of this Agreement as well as the right

of BROWN to collect any accrued royalties as recited in Article 3.

                    ARTICLE 8 - INDEMNIFICATION AND INSURANCE

     8.1 Indemnification. Except as provided in the RESEARCH AGREEMENT, LICENSEE
agrees to hold harmless, indemnify and defend BROWN and its officers, trustees
and employees, from all liabilities, demands, damages, expenses and losses
arising out of (a) use by LICENSEE, or by any party acting on behalf of or under
authorization from LICENSEE, of the TECHNOLOGY or PATENT RIGHTS; and (b) use,
sale or other disposition by LICENSEE, or by any party acting on behalf of or
under authorization from LICENSEE, of LICENSED PRODUCTS. The provisions of this
Article 8 shall survive termination of this Agreement.

     8.2 Insurance. LICENSEE shall carry the appropriate insurance coverage in
order to carry out the terms of this Article 8. Neither LICENSEE nor any
sublicensee shall commence clinical trials, or selling on a commercial basis
devices for the treatment of human subjects incorporating the PATENT RIGHTS
without having first presented to BROWN evidence that it has obtained liability
insurance reasonably acceptable to BROWN, provided that such insurance is
available to LICENSEE or its sublicensee on commercially reasonable terms.
Should LICENSEE or sublicensee be unable to obtain such coverage then the
parties hereto agree to consider in good faith reasonable alternatives for the
protection of Brown University against third party liability.

                                      -9-

<PAGE>

                             ARTICLE 9 - ASSIGNMENT

     BROWN agrees that its rights and obligations under this Agreement may not
be transferred or assigned without the prior written consent of LICENSEE.
LICENSEE may assign or otherwise transfer this Agreement and the license granted
hereby and the rights acquired by it hereunder only if such assignment or
transfer is accompanied by a sale or other transfer of LICENSEE's entire
business or of that part of LICENSEE's business to which the license granted
hereby relates; provided, that any such assignee or transferee has agreed in
writing to be bound by the terms and provisions of this Agreement. Upon such
assignment or transfer and agreement by such assignee or transferee, the term
LICENSEE as used herein shall mean such assignee or transferee.

                        ARTICLE 10 - EXPORT REQUIREMENTS

     10.1 License to Export. Any and all licenses, permits or other governmental
approvals for the export of materials, data, know-how, and the like carried out
under this Agreement by LICENSEE shall be the responsibility of LICENSEE.

                ARTICLE 11 - PAYMENTS, NOTICES AND COMMUNICATIONS

     Except as otherwise provided for herein, any payment, notice or other
communication pursuant to this Agreement shall be sufficiently made or given (i)
on the date of hand delivery if delivered with written receipt at the
addressee's address below or such address as the addressees shall designate by
written notice given to the other party or (ii) five (5) business days after the
date of mailing if sent to such party by certified first class mail, return
receipt requested, postage prepaid, addressed to it at its address below or as
it shall designate by written notice given to the other party.

     In the case of BROWN:     Brown University Research Foundation
                               42 Charlesfield Street
                               Box 1949 Providence, RI 02912
                               ATTN: William M. Jackson, President

     In the case of LICENSEE:  Spectra Science Corporation
                               300 Metro Center
                               Warwick,RI 02886
                               ATTN: Nicholas Kondon, CEO

                      ARTICLE 12 - MISCELLANEOUS PROVISIONS

     12.1 Limitation of Liability. Neither party shall be liable to the other
for any punitive, special, consequential, incidental or indirect damages arising
out of this Agreement, however caused, under any theory of liability.

                                      -10-

<PAGE>

     12.2 Governing Law. This Agreement shall be construed, governed,
interpreted and applied in accordance with the laws of the State of Rhode
Island, U.S.A., except that questions affecting construction and effect of any
patent shall be determined by the law of the country in which the patent was
granted.

     12.3 Entire Agreement. The parties hereto acknowledge that this instrument,
together with the RESEARCH AGREEMENT, sets forth the entire agreement and
understanding of the parties hereto as to the subject of the matter hereof, and
shall not be subject to any change or modification except by the execution of a
written instrument subscribed to by the parties hereto.

     12.4 Severability. The provisions of this Agreement are severable, and in
the event that any, provisions of this Agreement are determined to be invalid or
unenforceable under any controlling body of law, such invalidity or
unenforceability shall not in any way effect the validity or enforceability of
the remaining provisions hereof.

     12.5 Disputes. Except as set forth in Section 7.2, any dispute, claim, or
difference arising in connection with this Agreement or as to the rights or
liabilities of the parties hereunder (each such event being hereinafter called a
"dispute"), shall be referred to arbitration in Providence, Rhode Island in
accordance with the Commercial Arbitration Rules of the American Arbitration
Association. The Arbitration tribunal shall consist of three arbitrators. The
party initiating arbitration shall nominate one arbitrator (who shall not be
affiliated with such party) in the request for arbitration and the other party
shall nominate a second arbitrator (who shall not be affiliated with such party)
in the answer thereto. The two arbitrators so named will then jointly appoint
the third arbitrator as chairman of the Arbitration Tribunal. In the event a
party shall fail to nominate its arbitrator or the two shall fail to nominate
the third, such nomination shall be made by the office of the American
Arbitration Association in Providence, Rhode Island. The Arbitration Tribunal
shall have no rights to award any damages except actual direct damages. The
award of the Arbitration shall be accompanied by a written decision explaining
the basis for the award. The award of the Arbitration tribunal shall be final
and judgment upon such an award may be entered in any competent court or
application may be made to any competent court for judicial acceptance of such
an award and an order of enforcement. In the event of any procedural matter not
covered by the aforesaid Rules, the procedural law of the State of Rhode Island
shall govern.

                            ARTICLE 14 - IMPROVEMENTS

     14.1 BROWN. Improvements to the TECHNOLOGY made by BROWN shall belong to
BROWN. BROWN hereby grants to LICENSEE a right to negotiate, in accordance with
the RESEARCH AGREEMENT and any other research support agreement, a
royalty-bearing license to all improvements which are not within the definition
of TECHNOLOGY but which are developed at BROWN by Nabil Lawandy or by BROWN
employees working with Nabil Lawandy under the RESEARCH AGREEMENT or other
research support agreement with LICENSEE.

     14.2 LICENSEE. BROWN shall have no right, title or interest in or to
improvements to the TECHNOLOGY made by LICENSEE, LICENSEE's SUBLICENSEES or
LICENSEE's consultants, contractors, subcontractors, joint venturers, customers
or the like, with the proviso that to the extent that a product or process
incorporating such improvements is within the scope of a LICENSED PRODUCT. the
terms and conditions of this Agreement apply.

                                      -11-

<PAGE>

     14.3 ROYALTIES. For products or processes incorporating improvements not
made, owned, or controlled by BROWN which are utilized in the manufacture, use
or sale of LICENSED PRODUCT, the royalties of Article 3 hereof will be
renegotiated in good faith to reflect the value of the technology made, owned,
or controlled by BROWN relative to the value of the improvement not made, owned,
or controlled. by BROWN except that to the extent the PATENT RIGHTS dominate the
improvements not made, owned, or controlled by BROWN the royalties due to BROWN
shall not be diminished pursuant to this Section.

BROWN UNIVERSITY RESEARCH FOUNDATION        SPECTRA SCIENCE CORPORATION

By: /s/ William M Jackson                   By: /s/ Illegible
    -----------------------------               -----------------------------

Title: President                            Title: Chief Executive Officer

Date: March 2, 1994                         Date: March 2, 1994

                                      -12-<PAGE>

                                                                   Exhibit 10.12

                                LICENSE AGREEMENT

         This AGREEMENT, effective this 15th day of April, 2002, ("EFFECTIVE
DATE") by and between BROWN UNIVERSITY RESEARCH FOUNDATION, a corporation duly
organized and existing under the laws of the State of Rhode Island and having a
principal office at 42 Charlesfield Street, Providence, Rhode Island 02912
("BURF") and Spectra Systems Corporation, Inc. a Delaware corporation having its
principal office at 321 South Main St., Providence, Rhode Island 02903
("LICENSEE").

         WHEREAS BURF is the owner by assignment from Brown University of
several patent applications and patents relating to the studies of Dr. Nabil
Lawandy conducted at Brown University; and

         WHEREAS, LICENSEE has expertise in commercial laser machining and
materials processing and is further assembling the capabilities needed to
develop the above referenced patent applications and patents into one or more
commercial products; and

         WHEREAS BURF desires to have its patents, inventions and proprietary
information used in the public interest and is willing to grant a license
thereto on the terms set forth below; and

         WHEREAS LICENSEE desires to obtain a license for such patents,
inventions and proprietary information rights for purposes which may include
developing commercial products upon the terms and conditions set forth below;

         NOW, THEREFORE in consideration of the premises and the mutual
covenants contained herein, the parties agree as follows:

                             ARTICLE 1 - DEFINITIONS

For the purpose of this Agreement, the following words and phrases shall have
the following meanings:

         1.1. "AFFILIATE" shall mean a corporation or other business entity
controlled by, controlling or under common control with, a party hereto. For
purposes of this Agreement, control of a corporation or other business entity
shall include direct or indirect beneficial ownership of fifty one percent (51%)
or more of the voting interest in, or a fifty one percent (51%) or greater
interest in the equity of, such corporation or other business entity.

         1.2 "CONFIDENTIAL INFORMATION" shall mean all information related to
the PATENT RIGHTS which is disclosed by one party to the other, to the extent
that such information, as of the date of disclosure, is not (a) known to the
receiving party (as

<PAGE>

demonstrated by competent documentary evidence); (b) disclosed in published
literature through no fault of the receiving party; (c) generally available to
industry; or (d) obtained by the receiving party from a third party without
binder of secrecy, provided, however, that such third party has no
confidentiality obligations to the disclosing party or to any of its affiliates
relating to the disclosed information.

         1.3 "FIRST COMMERCIAL SALE" shall mean the initial transfer by
LICENSEE, or any of its AFFILIATES or sublicensees, to an unrelated third party
of LICENSED PRODUCTS for commercial use and not for research, development or
testing purposes.

         1.4 "Licensed product" shall mean any product, device, software,
protocol, process or service, the manufacture, use or sale of which is within
the claims of PATENT RIGHTS.

         1.5 "PATENT RIGHTS" shall mean (a) all United States and foreign patent
applications listed in Exhibit A hereto; and (b) any additions, continuations,
continuations-in-part, divisions, reissues or renewals and extensions based
thereon. PATENT RIGHTS shall not include any patent or patent application
(additions, continuations, continuations-in-part, divisions, reissues or
renewals or extensions based thereon) as to which LICENSEE shall have
surrendered its rights under Section 5.3 or 7.4 hereof.

         1.6 "GOVERNMENT RIGHTS" shall mean the rights of the United States of
America, as set forth in Public Laws 96-517 and 98-620 (35 U.S.C.(S)200 et seq.)
or any successor thereto, as well as federal regulations promulgated thereunder,
all as modified and in effect from time to time.

         1.7 "TERRITORY" shall mean the world.

                                ARTICLE 2 - GRANT

         2.1 Grant. BURF hereby grants to LICENSEE, subject to the terms herein
recited, the exclusive except for the Government Rights-, transferable , right
and license under the PATENT RIGHTS with the right to grant sublicenses, to (i)
make, have made, use, sell and distribute (directly or indirectly through third
parties) LICENSED PRODUCTS in the TERRITORY; and (ii) to practice the Patent
Rights (collectively, the "License Grant"). LICENSEE agrees that for so long as
this license remains exclusive in the United States any LICENSED PRODUCT
produced for sale in the United States will be manufactured substantially in the
United States unless otherwise permitted under applicable law.

         2.2 Reservation of Research Rights. Anything to the contrary
notwithstanding, BURF, reserves the right to use (and to permit Brown University
to use) the PATENT RIGHTS and CONFIDENTIAL INFORMATION for its own research and
educational non-commercial purposes, subject to the confidentiality provisions
of this Agreement.

         2.3 Rights of the Federal Government. Any right granted in this
Agreement greater than that permitted by the Government Rights shall be subject
to modification as may be

Page 2 of 14

<PAGE>

required to conform to the provisions of the Government Rights. BURF shall take
all action necessary pursuant to the Government Rights to preserve its ownership
of all PATENT RIGHTS.

                             ARTICLE 3 - LICENSE FEE

         3.1 License Fee. LICENSEE shall grant BURF a license issue fee of [***]

         3.2 Royalties. No royalties shall be due BURF with respect to the
License Grant or any sublicenses thereof.

                         ARTICLE 4 - REPORTS AND RECORDS

         4.1 Reports. Upon the request of BURF, LICENSEE shall report to BURF on
its efforts to bring the PATENT RIGHTS into commercial use. BURF shall keep all
information furnished under this Article 4 confidential.

         4.2 Marking. LICENSEE and its sublicensees agree to mark all LICENSED
PRODUCTS sold in the United States with all applicable U.S. patent numbers to
the extent commercially practicable. All LICENSED PRODUCTS shipped to or sold in
other countries shall be marked in such a manner as to conform with the patent
laws and practice of the country to which such products are shipped or in which
such products are sold, to the extent commercially practicable.

                 ARTICLE 5 - PATENT PROSECUTION AND ENFORCEMENT

         5.1 BURF and LICENSEE shall cooperate fully in the preparation, filing,
prosecution, maintenance and defense of the PATENT RIGHTS and of all patents and
patent applications licensed to LICENSEE hereunder, executing all papers and
instruments or requiring inventors to execute such papers and instruments so as
to enable BURF to apply for, to prosecute and to maintain patent applications
and patents in BURF's name in any country, using counsel of LICENSEE's
selection. Each party shall provide to the other prompt notice as to all matters
which come to its attention and which may affect the preparation, filing,
prosecution, maintenance or defense of any such patent applications or patents.

         5.2 LICENSEE shall reimburse BURF for all reasonable expenses incurred
by BURF for the preparation, filing, prosecution and maintenance of PATENT
RIGHTS except those previously reimbursed by LICENSEE or third parties. LICENSEE
shall pay BURF within thirty (30) days of receipt of invoices from BURF. Late
payment of these amounts shall be subject to interest charges at an annual rate
of one and one-half percent (1 1/2%) in excess of

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

Page 3 of 14

<PAGE>

the prime rate published from time to time in the Wall Street Journal. BURF
shall take responsibility for the preparation, filing, prosecution and
maintenance of such patent applications and patents and shall furnish to
LICENSEE copies of documents relevant to any such preparation, filing,
prosecution or maintenance. If BURF fails promptly to take any action reasonably
requested by LICENSEE and LICENSEE reasonably determines that such failure will
materially and adversely affect the PATENT RIGHTS, LICENSEE, in the name and as
the agent of BURF, may take all such action.

         5.3 If LICENSEE elects to no longer pay the expenses of a patent
application or patent included within PATENT RIGHTS, LICENSEE shall notify BURF
not less than sixty (60) days prior to such action and shall thereby surrender
its rights under such patent or patent application on a country by country
basis.

         5.4 Enforcement. BURF and LICENSEE shall each give immediate notice to
the other of any infringement of PATENT RIGHTS by third parties which may come
to their attention. BURF hereby grants LICENSEE, at LICENSEE's expense, the
right to institute and conduct such legal action against third party infringers
of the PATENT RIGHTS, or enter into such settlement agreements, as are deemed
appropriate by LICENSEE. The benefits of any action taken by LICENSEE shall be
retained by LICENSEE. In any such action, LICENSEE shall be entitled to join
BURF as a party plaintiff and BURF will be obligated to reasonably assist at
LICENSEE's expense. Should LICENSEE fail to commence actions or proceedings
against infringers of the PATENT RIGHTS within sixty (60) days of receiving
written notice thereof from BURF, BURF, at BURF's expense, shall have the right
to initiate and pursue such action and receive all resulting benefits. If BURF
fails to take such action within sixty (60) days of receiving written notice
from LICENSEE, LICENSEE shall again have such right and authority to take such
actions as set forth in this Section 5.4. No settlement, consent judgment or
other voluntary final disposition of the suit may be entered into without the
consent of BURF, which consent shall not be unreasonably withheld, delayed or
conditioned.

                   ARTICLE 6 - REPRESENTATIONS AND WARRANTIES

         6.1 Utilization. LICENSEE may take such steps as LICENSEE may deem
appropriate to commercialize the PATENT RIGHTS.

         6.2 Patent Ownership. BURF represents and warrants that it is the owner
of the PATENT RIGHTS by virtue of assignment from the inventors of PATENT
RIGHTS.

         6.3 Authority. Each party represents and warrants that it has the right
and authority to enter this Agreement.

         6.4 Exceptions. Nothing in this Agreement shall be construed as:

             (A) a warranty or representation that anything made, used, sold or
otherwise disposed of under any license granted in this Agreement is or will be
free from infringement of patents, copyrights and trademarks of third parties;
provided, however, that BURF has not

Page 4 of 14

<PAGE>

received any notice or claim that the Patent Rights infringe upon the
intellectual property of any third party.

             (B) conferring rights on BURF to use in advertising, publicity or
otherwise the name of LICENSEE or of its employees, AFFILIATES or Sublicensees
without the prior written approval of LICENSEE; or

             (C) conferring rights on LICENSEE or Sublicensees to use in
advertising or publicity the name of "Brown University", "Brown University
Research Foundation" or their staff and employees without the prior written
approval of BURF.

         6.5 Disclaimer. EXCEPT AS EXPRESSLY PROVIDED HEREIN, BURF MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE. THE PARTIES ACKNOWLEDGE THAT THIS AGREEMENT IS
NOT A CONSUMER TRANSACTION UNDER THE UNIFORM COMMERCIAL CODE OF RHODE ISLAND.

         6.6 LICENSEE Representations and Warrants . LICENSEE covenants,
represents and warrants to BURF as follows:

           6.6.1 Corporate Existence; Compliance with Law. LICENSEE: (i) is duly
                 organized, validly existing and in good standing under the laws
                 of the State of Delaware, and (ii) is duly qualified to do
                 business as a foreign corporation under the laws of the State
                 of Rhode Island.

           6.6.2 Power; Authorization; Enforceable Obligations. LICENSEE has all
                 requisite power and authority to execute, deliver and perform
                 this License Agreement and has taken all necessary action to
                 authorize the License Agreement and issuance of shares
                 hereunder. This License Agreement, has been duly executed and
                 delivered on behalf of LICENSEE and constitutes a legal, valid
                 and binding obligation of LICENSEE enforceable against LICENSEE
                 in accordance with its terms, except as enforceability may be
                 limited by applicable bankruptcy, insolvency, reorganization,
                 moratorium or similar laws affecting the enforcement of
                 creditors' rights generally.

           6.6.3 Capitalization. The authorized capital stock of LICENSEE as of
                 the date hereof consists of 23,000,000 shares of Common Stock,
                 $0.01 per share, and 10,007,178 shares of Preferred Stock, par
                 value $0.01 per share, of which 1,059,869 shares of Common
                 Stock and 9,214,744 shares of Preferred Stock are issued and
                 outstanding.

           6.6.4 Authorization and Issuance of Shares. The issuance of the
                 Shares has been duly authorized and, upon delivery to BURF of
                 certificates therefore against payment in fulfillment of all
                 obligations hereunder in accordance with the

Page 5 of 14

<PAGE>

                 terms hereof, such Shares will have been validly issued and
                 fully paid and will be non-assessable.

           6.6.5 No Legal Bar. The authorization, execution, delivery and
                 performance of this License Agreement by LICENSEE will not
                 violate any requirement of law or any contractual obligation.

           6.6.6 No Litigation. No litigation, investigation or proceeding is
                 pending or, to the best knowledge of LICENSEE, threatened by or
                 against LICENSEE or any officer, director or employee thereof
                 which might reasonably be expected to have a material adverse
                 effect on the business, operations, property, prospects or
                 financial or other condition of LICENSEE.

       6.7 BURF Representations and Warranties. BURF covenants, represents and
           warrants to LICENSEE as follows:

           6.7.1 BURF is aware of LICENSEE's business affairs and financial
                 condition and has acquired sufficient information about
                 LICENSEE to reach an informed and knowledgeable decision to
                 acquire the securities. BURF is acquiring these securities for
                 investment for BURF's own account only and not with a view to,
                 or for resale in connection with, any "distribution" thereof
                 within the meaning of the Securities Act of 1933. BURF is an
                 "accredited investor" as that term is defined under Rule 501
                 promulgated under the Securities Act of 1933.

           6.7.2 BURF understands that the securities have not been registered
                 under the Securities Act by reason of a specific exemption
                 therefrom, which exemption depends upon, among other things,
                 the bona fide nature of BURF's intent as expressed herein. In
                 this connection, BURF understands that, in the view of the
                 Securities and Exchange Commission, the statutory basis for
                 such exemption may not be present if BURF's representations
                 meant that BURF's present intention was to hold these
                 securities for a minimum capital gains period under the tax
                 statutes, for a deferred sale, for a market rise, for a sale if
                 the market does not rise, or for a year or any other fixed
                 period in the future.

           6.7.3 BURF further acknowledges and understands that the securities
                 must be held indefinitely unless they are subsequently
                 registered under the Securities Act or an exemption from such
                 registration is available. BURF further acknowledges and
                 understands that LICENSEE is under no obligation to register
                 the securities. BURF understands that the certificate
                 evidencing the securities will be imprinted with a legend that
                 prohibits the transfer of the securities unless they are
                 registered or such registration is not required in the opinion
                 of counsel satisfactory to LICENSEE.

           6.7.4 BURF is aware of the adoption of Rule 144 by the Securities and
                 Exchange Commission, promulgated under the Securities Act,
                 which permits limited

Page 6 of 14

<PAGE>

                 public resale of securities acquired in a non-public offering
                 subject to the satisfaction of certain conditions.

          6.7.5  BURF further acknowledges that in the event that all of the
                 requirements of Rule 144 are not met, compliance with
                 Regulation A or some other registration exemption will be
                 required; and that although Rule 144 is not exclusive, the
                 staff of the Securities and Exchange Commission has expressed
                 its opinion that persons proposing to sell private placement
                 securities other than in a registered offering and other than
                 pursuant to Rule 144 will have a substantial burden of proof in
                 establishing that an exemption from registration is available
                 for such offers or sales and that such persons and the brokers
                 who participate in the transactions do so at their own risk.

          6.7.6  Authorization; Enforceable Obligations. This License Agreement
                 has been duly authorized, executed and delivered by BURF and
                 constitutes a legal, valid and binding obligation of BURF
                 enforceable against BURF in accordance with its terms, except
                 as enforceability may be limited by applicable bankruptcy,
                 insolvency, reorganization, moratorium or similar laws
                 affecting the enforcement of creditors' rights generally.

          6.7.7  Each of the inventors listed on the patent applications
                 associated with the Patent Rights have executed assignment
                 agreements assigning all right, title, and interest to such
                 Patent Rights to BURF.

       6.8 Registration under Securities Act; Transfer. BURF (i) understands and
agrees that the Shares have not been registered or qualified under the
Securities Act or any state securities or blue sky laws, because the offer,
issuance and sale of said Shares is exempt from the registration or
qualification requirements of the Securities Act and applicable state securities
or blue sky laws; (ii) acknowledges that reliance on said exemptions is
predicated in part on the accuracy of BURF's representations, warranties and
covenants in this Section; (iii) understands and agrees that the Shares being
acquired by BURF hereunder must be held by BURF indefinitely unless a subsequent
disposition thereof is registered or qualified under the Securities Act and
applicable state securities or blue sky laws or is exempt from registration or
qualification, and that LICENSEE is not required to register or qualify the
Shares or to take any action to make such an exemption available; and (iv)
acknowledges that (a) there is no public market for the Shares, (b) there can be
no assurance that any such market will ever develop, and (c) there can be no
assurance that BURF will be able to liquidate BURF's investment in LICENSEE.

                        ARTICLE 7 - TERM AND TERMINATION

       7.1 Bankruptcy. If LICENSEE undergoes a liquidation in bankruptcy, or
files a petition for liquidation in bankruptcy, or receiver, trustee or assignee
for the benefit of creditors, whether by the voluntary act of LICENSEE or
otherwise, and if LICENSEE fails to terminate any such proceeding within one
hundred twenty (120) days after its commencement, BURF may at its election
terminate this Agreement upon thirty (30) days written notice to LICENSEE.

Page 7 of 14

<PAGE>

LICENSEE agrees to provide written notice to BURF of LICENSEE's or third party's
intention to file a petition for liquidation of LICENSEE in bankruptcy prior to
such filing, if known.

         7.2 Material Breach. Upon any material breach or default by LICENSEE,
BURF shall have the right to terminate this Agreement and the rights and license
granted hereunder by ninety (90) days notice by certified mail to LICENSEE. Such
termination shall become effective at the end of such ninety (90) day period
unless LICENSEE has cured any such breach or default prior to the expiration of
the ninety (90) day period.

       7.3 Termination by LICENSEE. LICENSEE may terminate this Agreement upon
ninety (90) days notice by certified mail to BURF. LICENSEE may terminate its
rights and obligations under this Agreement as to any patent included in the
PATENT RIGHTS upon ninety (90) days notice by certified mail to BURF.

       7.4. Obligations on Termination. Upon termination of this Agreement for
any reason, nothing herein shall be construed to release either party of any
obligation which matured prior to the effective date of such termination, and
LICENSEE may, after the effective date of such termination, complete LICENSED
PRODUCTS in the process of or manufacture at the time of such termination and
sell the same together with LICENSED PRODUCTS in inventory.

       7.5 Sublicenses. Any sublicenses granted by LICENSEE under this Agreement
shall provide for termination or assignment to BURF, at the option of BURF, of
LICENSEE'S interest therein upon termination of this Agreement.

       7.6 Survival. Article 8 and 7.4 shall survive termination of this
Agreement.

                    ARTICLE 8 - INDEMNIFICATION AND INSURANCE

       8.1 Indemnification. Except as provided below, LICENSEE shall indemnify,
defend and hold harmless BURF, BROWN UNIVERSITY and their trustees, officers,
professional staff, employees, agents and their respective successors, heirs and
assigns (the "Indemnitees"), against any liability, damage, loss or expense
(including reasonable attorneys' fees and expenses of litigation) incurred by or
imposed upon the Indemnitees or any one of them in connection with any claims,
suits, actions, demands or judgments arising out of (i) any theory of product
liability (including, but not limited to, actions in the form of tort, warranty,
or strict liability) concerning any product, process of service made, used or
sold pursuant to any right or license granted under this Agreement, or (ii) the
exercise by LICENSEE of the rights and licenses granted to LICENSEE under this
Agreement. LICENSEE shall have no obligation to indemnify any of the Indemnitees
under this Article 8 to the extent that a court of competent jurisdiction or an
arbitrator pursuant to Article 12 determines that the damages were the result of
the fraud, gross negligence or willful misconduct of the Indemnitees. LICENSEE
reserves all rights it may have against the Indemnitees arising by reason of
such fraud, gross negligence or willful misconduct.

Page 8 of 14

<PAGE>

       8.2. Defense. LICENSEE agrees, at its own expense, to provide attorneys
reasonably acceptable to BURF to defend against any actions brought or filed
against any party indemnified hereunder with respect to the subject of indemnity
contained herein, whether or not such actions are rightfully brought.

       8.3  Insurance. Beginning at the time of the FIRST COMMERCIAL SALE,
LICENSEE shall, at its sole cost and expense, procure and maintain comprehensive
general liability insurance in amounts consistent with the prudent industry
practice, naming the Indemnitees as additional insureds, to the extent they may
be so named without material increase in the premium. To the extent available on
commercially reasonable terms and rates, such comprehensive general liability
insurance shall provide (i) product liability coverage and (ii) broad form
contractual liability coverage for LICENSEE's indemnification under this
Agreement. LICENSEE shall provide BURF with written evidence of such insurance
upon request of BURF. To the extent available on commercially reasonable terms
and rates LICENSEE shall maintain such comprehensive general liability insurance
beyond the expiration or termination of this Agreement during the period that
any product, process, or service, relating to, or developed pursuant to, this
Agreement is being commercially distributed or sold by LICENSEE or by an agent
of LICENSEE and for a reasonable period after the period thereafter. LICENSEE
shall notify BURF in the event any insurance is not available as provided
herein. If such insurance is not available on commercially reasonable terms,
LICENSEE will not sell, distribute or otherwise dispose of LICENSED PRODUCTS
unless and until LICENSEE and BURF have agreed to a reasonable arrangement or
accomodation to protect the Indemnitees from exposure to product liability
claims.

       8.4  Sublicense. Without in any way limiting LICENSEE'S Indemnification
obligations hereunder, LICENSEE shall require all of its sublicensees hereunder
to indemnify and hold harmless BURF and Brown University under the same terms as
stated in Section 8.1 and to carry insurance under the same terms as Section
8.3.

                             ARTICLE 9 - ASSIGNMENT

       9.1  BURF agrees that its rights and obligations under this AGREEMENT may
not be transferred or assigned without the prior written consent of LICENSEE.
LICENSEE may assign or otherwise transfer this Agreement and the license granted
hereby and the rights acquired by it hereunder only if such assignment or
transfer (a) is to an AFFILIATE or (b) is accompanied by the sale or transfer of
LICENSEE's entire business or of that part of LICENSEE'S business to which the
license granted hereby relates; provided, that any assignee or transferee has
agreed in writing to be bound by the terms and provisions of this AGREEMENT .
Upon such assignment or transfer and agreement by such assignee or transferee,
the term LICENSEE as used herein shall include such assignee or transferee.

                        ARTICLE 10 - EXPORT REQUIREMENTS

       10.1 License to Export. Any and all licenses, permits or other
governmental approvals for the export of materials, data, know-how, and the like
carried out under this Agreement by LICENSEE shall be the responsibility of
LICENSEE.

<PAGE>

                ARTICLE 11 - PAYMENTS, NOTICES AND COMMUNICATIONS

         11.1 Any payment, notice or other communication pursuant to this
Agreement shall be sufficiently made or given on the date of mailing if sent to
such party by certified first class mail, postage prepaid, addressed to it at
its address below or as it shall designate by written notice given to the other
party:

         In the case of BURF:

                                           Brown University Research Foundation
                                           42 Charlesfield Street
                                           Box 1949
                                           Providence, RI 02912
                                           Attention: President

         In the case of LICENSEE:
                                           Spectra Systems Corporation
                                           321 South Main Street
                                           Providence, RI 02903
                                           Attention: President

         With a required copy to:

                                           Kirkpatrick & Lockhart LLP
                                           75 State Street
                                           Boston, MA 02109
                                           Attn: Michael A. Hickey

Page 10 of 14

<PAGE>

                            ARTICLE 12 - ARBITRATION

         12.1 Any controversy arising under or related to this Agreement, or any
disputed claim by either party against the other under this Agreement excluding
any dispute relating to patent validity or infringement arising under this
Agreement, shall be settled by arbitration in accordance with the Licensing
Agreement Arbitration Rules of the American Arbitration Association. Upon
request of either party, arbitration will be by:

              a. A third party arbitrator mutually agreed upon in writing by
LICENSEE and BURF within thirty (30) days of such arbitration request; or

              b. A member of the American Arbitration Association.

         12.2 Judgment upon the award rendered by the Arbitrator may be entered
in any court having jurisdiction thereof. The parties shall be entitled to
discover in like manner as if the arbitration were a civil suit in the Rhode
Island Superior Court.

         12.3 Any arbitration shall be held in Providence, Rhode Island, unless
the parties hereto mutually agreed in writing to another place.

                      ARTICLE 13 - MISCELLANEOUS PROVISIONS

         13.1 Confidentiality. During the duration of this Agreement and for a
period of five (5) years thereafter, each party agrees to use reasonable efforts
not to (i) disclose to third parties any CONFIDENTIAL INFORMATION of the other
party or (ii) use the CONFIDENTIAL INFORMATION of the other party in any manner
except as contemplated by this Agreement. Nothing in this Agreement shall limit
in any way the disclosure of information required by a public authority of the
disclosure of information that is necessary to prevent imminent danger to the
public.

         13.2 Limitation of Liability. Neither party shall be liable to the
other for any special, consequential, incidental or indirect damages arising out
of this Agreement, however caused, under any theory of liability.

         13.3 Governing Law. This Agreement shall be construed, governed,
interpreted and applied in accordance with the laws of the State of Rhode
Island, U.S.A., except that questions affecting construction and effect of any
patent shall be determined by the law of the country in which the patent was
granted.

         13.4 Entire Agreement. The parties hereto acknowledge that this
instrument sets forth the entire agreement and understanding of the parties
hereto as to the subject matter hereof, and shall not be subject to any change
or modification except by the execution of a written instrument subscribed to by
the parties hereto.

Page 11 of 14

<PAGE>

         13.5 Severability. The provisions of this Agreement are severable, and
in the event that any provisions of this Agreement are determined to be invalid
or unenforceable under anycontrolling body of law, such invalidity or
enforceability shall not in any way affect the validity or enforceability of the
remaining provisions hereof.

                            ARTICLE 14 - IMPROVEMENTS

         BURF shall have no right, title or interest, in or to improvements to
the TECHNOLOGY made by LICENSEE, LICENSEE's sublicensees or LICENSEE'S
consultants, contractors, subcontractors, joint venturers, customers or the
like, except that to the extent that a product or process incorporating such
improvements is within the scope of a LICENSED PRODUCT, the terms and conditions
of this Agreement apply.

BROWN UNIVERSITY RESEARCH                    SPECTRA SYSTEMS
FOUNDATION                                   CORPORATION

By: /s/ William Jackson                      By:  /s/ Nabil M. Lawandy
    -------------------------                     -------------------------

Title:                                       Title:
       ----------------------                       -----------------------

Date:                                        Date:
      -----------------------                      ------------------------

                                    EXHIBIT A

                     List of patent applications and patents

   [***]

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

Page 12 of 14

<PAGE>

[*] = Information redacted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with
the Commission.

Page 13 of 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}]]